This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ascend Biopharmaceuticals Ltd.
Drug Names(s): Ad-IFNgamma, TG1042
Description: Ad-IFNgamma expresses the human interferon gamma (IFNgamma) cytokine, inducing an antitumoral immunity. Ad-IFNgamma is a non-propagative adenovirus type 5 (Ad5) with a nucleotidic sequence encoding human IFNgamma.
Transgene and Ascend
In June 2013, Transgene and Ascend entered into an exclusive worldwide licence agreement to develop ASN-002 (TG1042). Ascend is initially focused on development for basal cell carcinoma, however the license agreement also grants Ascend the rights to develop in bladder cancer and an additional indication to be selected by Ascend.
Partners: Transgene S.A.
Additional information available to subscribers only: